BioFilm Control
Biotechnology R&D company


BioFilm Control is working on “one of the most serious threats to global health”, as described by the WHO: antibiotic resistance. Today, 700,000 people worldwide die each year from resistance to various existing antimicrobial treatments; but without a solution, projections to 2050 put the number at 10 million. Antibiotics are the mainstay of modern medicine: if they lose their effectiveness, even routine medical procedures could become dangerous. “The world is ill-prepared for the threat of antibiotic resistance”, said the Assistant Director-General for Health Security at WHO, warning of the dawn of a “post-antibiotic era”, which would be a return to the previous centuries. COVID 19 sheds new light on the potential for health crises on a global scale; although new antibiotics are in development, none of them will be effective against the more dangerous forms of antibiotic-producing bacteria.

In 15 years of research, against an approach that tends to create increasingly powerful antibiotics, we have opened a path in an unexplored area: attacking a source that makes antibiotics ineffective: the biofilm. A viscous film, produced by the microbes themselves, and which protect them in a matrix insensitive to any form of aggression. In this shielding, bacteria are 1000 times more effective. Involved in 80% of human infections and 60% of nosocomial infections, it is one of the main causes of antibiotic resistance. These biofilms form on living surfaces: human tissue – including the skin, lungs and heart – but also non-living surfaces, such as medical devices.

Thierry Bernardi, founder of BioFilm Control: “Current remedies against the development of biofilms are very limited. These bacteria, which form a biofilm, lead us to a potential therapeutic impasse. We now provide two levels of response; from 2021, with a biofilm diagnostic tool that indicates the best antibiotic available to curb infection; and by 2028, with the development of a new class of antimicrobial drug to precisely prevent the appearance of the biofilm. We are the only ones in the world to design this pure anti-biofilm, which can be used across the board with any antibiotic. Our test and our drug will create a virtuous circle: more efficiency, fewer chronic infections, fewer hospital patients, fewer antibiotics, less strain on the healthcare system. We are in the public interest, globally, with a solution that will help eradicate antibiotic resistance.”


The management team

Thierry Bernardi
Manager & Founder

Thierry Bernardi is the founder of BioFilm Control and the inventor of the BioFilm Ring Test®. He has co-authored eight publications and ten patents concerning BioFilm Ring Test® technology. Before founding BioFilm Control, he held several R&D and Business Development positions in start-ups and multinational companies. In 1991, he obtained his Pharm.D from the University of Montpellier (France).

Stéphanie Badel-Berchoux
Microbiology Lab Manager
Head of Production

Following a doctorate in Biochemistry-Microbiology, Stéphanie Badel-Berchoux joined BioFilm Control in 2011. Responsible for the laboratory and a team of 8 people, she is also your privileged contact for all your service requests.
Stéphanie has studied the impact of exopolymers in the structuring of biofilms and specializes in the relationship between the composition of microbiota and their biofilms.